UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER

Texas AG Ken Paxton sues Dallas doctor Dr. May Chi Lau for providing transgender care to 21 minors, violating state law banning such treatments. Lau could face license loss and hefty fines if found guilty.

FDA advisors voted 10-6 for elamipretide as a treatment for Barth syndrome, despite limited evidence. The decision was influenced by the drug's potential benefits and the rarity of the disease, which makes large-scale trials difficult.

RI-AG03, a peptide inhibitor, effectively prevents Tau protein accumulation in Alzheimer's disease, targeting both key regions of the protein. Tested in fruit flies and biosensor cells, it extended life and reduced aggregation, with plans for rodent trials before clinical testing.

Scientists developed a drug, RI-AG03, targeting tau proteins to combat Alzheimer’s, showing efficacy in lab and fruit fly studies. The drug inhibits key regions affected by the disease, potentially offering more effective treatment with fewer side effects.

Researchers developed RI-AG03, a peptide inhibitor targeting Tau protein aggregation hotspots, showing efficacy in preventing aggregation and extending lifespan in fruit fly models, with potential for Alzheimer’s treatment.

Researchers developed a drug, RI-AG03, targeting tau protein clumping in Alzheimer's disease, extending fruit fly lifespan and reducing tau aggregation in cells. Plans for rodent testing precede potential clinical trials, despite past failures of tau-based therapies.

New drug RI-AG03 targets tau protein to prevent Alzheimer’s-related neurodegeneration, inhibiting tau aggregation at two key regions. Preliminary tests on fruit flies and cells show promising results, with plans for rodent trials before clinical testing.

A drug, RI-AG03, developed by an international team led by Lancaster University, targets both major aggregation-promoting 'hotspots' of the tau protein, key to Alzheimer's Disease. Effective in preventing tau buildup in lab and fruit fly studies, it could lead to more targeted and safer treatments for neurodegenerative diseases.

Rivus Pharmaceuticals' weight loss drug, HU6, showed muscle-sparing benefits in a Phase IIa trial for obese patients with heart failure with preserved ejection fraction (HFpEF), meeting primary and secondary endpoints including weight loss, blood pressure reduction, and improved cardiac structure and function.